40 results on '"Han, Yingshan"'
Search Results
2. Publisher Correction: Regulation of protein kinase Cδ Nuclear Import and Apoptosis by Mechanistic Target of Rapamycin Complex-1
3. Regulation of protein kinase Cδ Nuclear Import and Apoptosis by Mechanistic Target of Rapamycin Complex-1
4. Neuroprotective Effects of Trophic Factors and Natural Products: Involvement of Multiple Intracellular Kinases
5. Monotherapy with either dolutegravir or raltegravir fails to durably suppress HIV viraemia in humanized mice
6. Purification of Zika virus RNA-dependent RNA polymerase and its use to identify small-molecule Zika inhibitors
7. Identification of resveratrol analogs as potent anti‐dengue agents using a cell‐based assay
8. Late Indosinian granitoids in the Zhacanggou, Guide Basin, NW China: Whole‐rock geochemistry, zircon U–Pb geochronology, Lu–Hf isotopes, and implications for magma mixing
9. The R263K substitution in HIV-1 subtype C is more deleterious for integrase enzymatic function and viral replication than in subtype B
10. Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity
11. Late Indosinian granitoids in the Zhacanggou, Guide Basin, NW China: Whole‐rock geochemistry, zircon U–Pb geochronology, Lu–Hf isotopes, and implications for magma mixing.
12. Comparative Neuroprotective Properties of Stilbene and Catechin Analogs: Action Via a Plasma Membrane Receptor Site?
13. Antimalarial drugs and their metabolites are potent Zika virus inhibitors
14. Investigational drugs for the treatment of Zika virus infection: a preclinical and clinical update
15. Erratum for Mesplède et al., “The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration”
16. P-I1 Monotherapy with integrase inhibitors does not maintain viral suppression in humanized mice with chronic HIV infection
17. The antimalarial drug amodiaquine possesses anti‐ZIKA virus activities
18. Investigational HIV integrase inhibitors in phase I and phase II clinical trials
19. Evaluation of Sofosbuvir (β-D-2′-deoxy-2′-α-fluoro-2′-β-C-methyluridine) as an inhibitor of Dengue virus replication #
20. The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration
21. JAK-STAT Signaling Pathways and Inhibitors Affect Reversion of Envelope-Mutated HIV-1
22. Identification of a Pyridoxine-Derived Small-Molecule Inhibitor Targeting Dengue Virus RNA-Dependent RNA Polymerase
23. The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound
24. Identification of an env-defective HIV-1 mutant capable of spontaneous reversion to a wild-type phenotype in certain T-cell lines
25. Purification of Zika virus RNA-dependent RNA polymerase and its use to identify small-molecule Zika inhibitors.
26. Neuroprotective Effects of Trophic Factors and Natural Products: Involvement of Multiple Intracellular Kinases
27. HIV-1 Group O Integrase Displays Lower Enzymatic Efficiency and Higher Susceptibility to Raltegravir than HIV-1 Group M Subtype B Integrase
28. The Connection Domain Mutation N348I in HIV-1 Reverse Transcriptase Enhances Resistance to Etravirine and Rilpivirine but Restricts the Emergence of the E138K Resistance Mutation by Diminishing Viral Replication Capacity
29. The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness
30. Role of the K101E Substitution in HIV-1 Reverse Transcriptase in Resistance to Rilpivirine and Other Nonnucleoside Reverse Transcriptase Inhibitors
31. Effect of Mutations at Position E138 in HIV-1 Reverse Transcriptase and Their Interactions with the M184I Mutation on Defining Patterns of Resistance to Nonnucleoside Reverse Transcriptase Inhibitors Rilpivirine and Etravirine
32. Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure
33. Enhancement of the cytotoxic potential of the mixed EGFR and DNA-targeting ‘combi-molecule’ ZRBA1 against human solid tumour cells by a bis-quinazoline-based drug design approach
34. Subunit-Selective Mutational Analysis and Tissue Culture Evaluations of the Interactions of the E138K and M184I Mutations in HIV-1 Reverse Transcriptase
35. FoxO-dependent and -independent mechanisms mediate SirT1 effects on IGFBP-1 gene expression
36. Neuroprotective Effects of Trophic Factors and Natural Products: Involvement of Multiple Intracellular Kinases.
37. Identification of a Pyridoxine-Derived Small-Molecule Inhibitor Targeting Dengue Virus RNA-Dependent RNA Polymerase
38. Identification of an env-defective HIV-1 mutant capable of spontaneous reversion to a wild-type phenotype in certain T-cell lines.
39. Subunit-Selective Mutational Analysis and Tissue Culture Evaluations of the Interactions of the E138K and M184I Mutations in HIV-1 Reverse Transcriptase.
40. Molecular mechanism of antagonism between the Y181C and E138K mutations in HIV-1 reverse transcriptase.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.